Our findings suggest that treatment with anti-TNF agents may improve insulin resistance and sensitivity in RA patients with active disease and high insulin resistance, and this effect correlates with reduced levels of the insulin-resistant Ser312-phosphorylated form of IRS-1 and increased levels of activated/phosphorylated AKT. This evidence concerns the gene INS and rheumatoid arthritis.